Protocols
17 protocol(s) meet the specified criteria
Disease Site: Liver
Protocol No.TitleStatus
04-RAD-507-ORCA Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma and Metastatic Disease to the Liver Open
AHEP0731Treatment of Children with All Stages of HepatoblastomaOpen
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaOpen
APEC1621SCNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)Open
GI15-225A pilot study of pembrolizumab in combination with Y90 radioembolization in patients with high risk hepatocellular carcinoma with preserved liver functionOpen
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
INCAGN1876-201A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination with Immune therapies in Subjects with Advanced or Metastatic MalignanciesOpen
LCCC1527Evaluation of the Chemotherapy Toxicity Risk Score for Treatment Decision in Elderly Patients with Advanced Solid CancerOpen
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
LCCC1705Quality of life in unresectable malignant biliary obstruction after biliary decompressionOpen
LCCC1706Qualitative analysis of quality of life in unresectable malignant biliary obstruction after biliary decompressionOpen
LCCC1734Adaptation of the Parenting Concerns Questionnaire for Patients with IllnessOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NC-6300-001A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaOpen
TARGET-HCCA 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular CarcinomaOpen
VEG116731A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid TumorsOpen